Citius Pharmaceuticals, Inc. - 8-K Filing

Citius Oncology reports 120% increase in LYMPHIR unit sales to U.S. wholesalers for fiscal Q4 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $CTXR

Read the full article at SEC EDGAR

More Regulatory news